Document Detail


Treating patients for cardiovascular protection: combination therapy to achieve complete renin-angiotensin system blockade.
MedLine Citation:
PMID:  17617778     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Inhibition of the renin-angiotensin system (RAS) with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) is a proven antihypertensive strategy. Understanding of the pathophysiologic effects of chronic RAS activation and clinical data indicate that RAS inhibition may exert beneficial effects in addition to blood pressure reduction. Studies indicate that monotherapy with ACE inhibitors and ARBs slows progression of diabetic and non-diabetic renal disease. Vascular protective effects of RAS inhibition have also been demonstrated in patients at high risk for cardiovascular events in the absence of significant blood pressure elevation or left ventricular dysfunction. Combining the complementary effects of ACE inhibitors and ARBs to achieve more complete RAS blockade is a promising approach to further reducing cardiovascular risk. This review will present the rationale for dual RAS inhibition, clinical data relating to its efficacy, and ongoing studies designed to evaluate its utility in patients at high risk for cardiovascular events.
Authors:
Alan H Gradman
Related Documents :
1387008 - Angiotensin ii receptor antagonist losartan has persistent effects on blood pressure in...
8562468 - Vascular protective effects of ace inhibitors and calcium antagonists: theoretical basi...
1728438 - Blood pressure control by the renin-angiotensin system in normotensive subjects. assess...
8722438 - Presence of cardiovascular structural changes in essential hypertensive patients with c...
1387008 - Angiotensin ii receptor antagonist losartan has persistent effects on blood pressure in...
2301618 - Pulsatile pressure can prevent rapid baroreflex resetting.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Preventive cardiology     Volume:  10     ISSN:  1520-037X     ISO Abbreviation:  Prev Cardiol     Publication Date:  2007  
Date Detail:
Created Date:  2007-07-09     Completed Date:  2007-09-18     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9813731     Medline TA:  Prev Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  147-55     Citation Subset:  IM    
Affiliation:
Department of Medicine, Western Pennsylvania Hospital, Pittsburg, PA 15224, USA. gradmanmd@aol.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Cardiovascular Diseases / drug therapy*
Drug Therapy, Combination
Humans
Renin-Angiotensin System / drug effects,  physiology
Stroke / prevention & control
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Metabolic syndrome is associated with coronary artery calcium in asymptomatic white Brazilian men co...
Next Document:  Angiotensin-converting enzyme inhibitors in acute myocardial infarction: a clinical approach.